

Substitute Form PTO-1449 (Modified)  <b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 16601-0021US1	Application No. 10/523,253
	Applicant Samuel Weiss		
	Filing Date January 26, 2005	Group Art Unit 1636	

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	1	WO 2004/035086	04/29/2004	WIPO				

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	2	Marusic, S. et al., "Local delivery of granulocyte macrophage colony- stimulating factor by retrovirally transduced antigen-specific T cells leads to severe, chronic experimental autoimmune encephalomyelitis in mice." Neuroscience Letters, Vol. 332, no. 3: 185-189, November 8, 2002.
	3	Maurer, M.H. et al., "Old friends in new constellations—the hematopoietic growth factors G-CSF, GM-CSF, and EPO for the treatment of neurological diseases." Current Medicinal Chemistry, Vol. 15, no. 14: 1407-1411, 2008.
	4	Pitzer, C. et al., "Granulocyte-colony stimulating factor improves outcome in a mouse model of amyotrophic lateral sclerosis." Brain, Vol. 131, no. pt. 12: 3335-3347, December 2008.
	5	Rutella, S. et al., "Granulocyte colony-stimulating factor: a novel mediator of T cell tolerance." Journal of Immunology, Vol. 175, no. 11: 7085-7091, December 1, 2005.
	6	Snir, O. et al., "G-CSF enhances the adhesion of encephalitogenic T cells to extracellular matrix components: a possible mechanism for exacerbation of multiple sclerosis." Journal of Neuroimmunology, Vol. 172, No. 1-2: 145-155, March 2006.
	7	Zavala, F. et al., "G-CSF therapy of ongoing experimental allergic encephalomyelitis via chemokine-and cytokine-based immune deviation." Journal of Immunology, Vol. 168, no. 4: 2011-2019, February 15, 2002.

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	